National Institute of Mental Health

• Scientific Meeting » The NIMH Director’s Innovation Speaker Series: America’s Hidden Mental Health Crisis - Alisa Roth and Phil Andrews
  One of the most horrific—and least acknowledged—effects of mass incarceration is the epidemic of mental illness in our jails and prisons. On June 13, 2019, Alisa Roth, journalist and author of Insane: America’s Criminal Treatment of Mental Illness, will explain how this happened—and how we can fix it. Phil Andrews is the Director of Crime […]
• Scientific Meeting » Suicide Risk Algorithm Applications in Healthcare Settings
  On June 5th and 6th, investigators will meet to identify and prioritize research needs in the application of predictive analytics using electronic health records in suicide prevention.
• Concept Clearance » Identification, Validation, and Manipulation of Neural Circuits Related to Mental Illness, in Non-human Primates
  The goal of this initiative is to support the identification, validation and manipulation of neural circuits that underlie cognitive, emotional, and social processes impacted in mental illnesses. The initiative is focused on probing psychiatrically relevant behavior through studies in non-human primates. This initiative is intended to complement existing NIMH-funded preclinical investigation of circuits which have […]
• Concept Clearance » BRAIN Initiative: Non-Invasive Neuromodulation - New Tools and Techniques for Spatiotemporal Precision
  The goal of this initiative is to support grant applications in two related but distinct areas. The first area involves developing and testing novel tools and methods of neuromodulation that go beyond the existing forms of neural stimulation. The second area involves the optimization of existing stimulation methods.
• Concept Clearance » Renewal of the National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental or Substance Use Disorders or Alcohol Addiction
  The goal of the NCDDG Program is to advance the discovery, preclinical development, and early proof of concept testing in humans of new pharmacologic and neuromodulatory approaches to treat mental disorders, substance use disorders (SUDs), or alcohol addiction, and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate […]